Gilead Sciences | GILD - Market Capitalization

Stock Price
146.23
Daily Change
2.95 2.06%
Monthly
23.61%
Yearly
46.74%
Q1 Forecast
137.58

Gilead Sciences reported $179.45B in Market Capitalization this February of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
AbbVie USD 371.63B 37.4B Feb/2026
Agios Pharmaceuticals USD 2.33B 402M Sep/2025
ALKERMES USD 4.95B 235M Sep/2025
Alnylam Pharmaceuticals USD 59.77B 17.25B Sep/2025
Amgen USD 184.41B 32.48B Feb/2026
Biogen USD 20.54B 2.13B Sep/2025
BioMarin Pharmaceutical USD 10.4B 142M Sep/2025
Bristol-Myers Squibb USD 91.8B 2.4B Sep/2025
Eli Lilly USD 1.02T 300.22B Feb/2026
Gilead Sciences USD 137.73B 184M Sep/2025
GlaxoSmithKline GBP 86.59B 22.54B Feb/2026
Glaxosmithkline GBP 106.96B 20.08B Feb/2026
Incyte USD 16.56B 3.38B Sep/2025
J&J USD 500.24B 67.44B Dec/2025
Merck USD 293.38B 83.74B Feb/2026
Moderna USD 10.09B 581M Sep/2025
Neurocrine Biosciences USD 13.92B 1.48B Sep/2025
Novartis USD 265.66B 9.48B Sep/2025
Pfizer USD 147.57B 12.48B Feb/2026
PTC Therapeutics USD 4.88B 1B Sep/2025
Regeneron Pharmaceuticals USD 81.12B 21.53B Dec/2025
Sanofi EUR 100.88B 4.46B Dec/2025
Sarepta Therapeutics USD 2.02B 336M Sep/2025
United Therapeutics USD 18.96B 6B Sep/2025
Vertex Pharmaceuticals USD 100.41B 13.91B Sep/2025